Ghana targets first locally manufactured vaccine by 2027-NVI

Ghana is making progress towards manufacturing its first vaccine locally by 2027, with the first of three essential bulk substances required for production already in the country.

The vaccine, expected to be a Tetanus-Diphtheria (Td) vaccine, is part of efforts to strengthen Ghana’s capacity to produce essential vaccines domestically and reduce its dependence on imported supplies.

Chief Executive Officer of the National Vaccine Institute (NVI), Dr Sodzi Sodzi-Tettey, says preparations are progressing as planned, expressing confidence that the country will meet its 2027 target.

He disclosed that the first of the three bulk substances needed to manufacture the vaccine had arrived in Ghana and was currently at the premises of Atlantic Life Sciences.

Dr Sodzi-Tettey provided the update during the commissioning of the Human Identification Laboratory, popularly known as the DNA Lab, and a Vaccine Research and Development Laboratory at the Noguchi Memorial Institute.

The facilities were commissioned by President John Dramani Mahama as part of efforts to strengthen Ghana’s scientific research, healthcare and biotechnology capabilities.

Providing an update on the vaccine manufacturing programme, Dr Sodzi-Tettey said the Institute remained committed to meeting the deadline set for the country’s first locally manufactured vaccine.

“We have set ourselves the timeline of 2027 to manufacture Ghana’s first vaccine, the Tetanus-Diphtheria vaccine, and we are really on track,” he said.

He further revealed that the arrival of the first bulk substance marked an important step towards achieving the target, with two more substances required for the production process.

“The update that I’ll provide here is that the first of our three bulk substances to be used for the vaccine is right in the country, and it’s on the premises of Atlantic Life Sciences,” he added.

The National Vaccine Institute’s target forms part of Ghana’s broader ambition to establish a sustainable local vaccine manufacturing industry and strengthen the country’s preparedness for future public health emergencies.

Local production is expected to improve access to essential vaccines, strengthen supply security and reduce the country’s reliance on international manufacturers.

The COVID-19 pandemic exposed the challenges faced by countries dependent on imported vaccines, particularly when global demand rises and access to essential medical supplies becomes constrained.

Ghana has since intensified efforts to develop the technical expertise, infrastructure and partnerships required to support domestic vaccine production.

The selection of the Tetanus-Diphtheria vaccine as the country’s first locally manufactured vaccine represents an important milestone in that ambition.

The update on vaccine production coincided with the commissioning of two specialised laboratory facilities at the Noguchi Memorial Institute.

The Human Identification Laboratory, also known as the DNA Lab, is expected to strengthen Ghana’s capacity in DNA analysis and human identification.

The Vaccine Research and Development Laboratory, meanwhile, is intended to support scientific research and development activities critical to advancing vaccine production and strengthening the country’s biomedical research capacity.

The facilities form part of wider efforts to position Ghana as a stronger player in scientific innovation, medical research and biotechnology development.

内容来自 Myjoyonline,版权归原作者所有。

阅读原文 ↗

用 HomepageTab 新标签页关注 RSS,打开浏览器就能看到更新。

安装 HomepageTab